Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 8, 2016, Pages 911-922

  Syn, Nicholas Li Xun ^a   Yong, Wei Peng ^a   Goh, Boon Cher ^a   Lee, Soo Chin ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

cancer genomics; cancer immunology; exosomes; immunotherapy; liquid biopsy; next generation sequencing; precision oncology; tumour microenvironment; whole exome sequencing; Whole genome sequencing

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CIRCULATING TUMOR CELL; EXOSOME; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; NATIONAL HEALTH ORGANIZATION; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MOLECULAR PROFILING; DISEASE COURSE; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PROCEDURES;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PRECISION MEDICINE; TUMOR MICROENVIRONMENT;

EID: 84979947914     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1196187     Document Type: Review

References (104)

1. T.Boveri Zur frage der entstehung maligner tumoren. Am Assoc Adv Sci. 1914. doi:10.1126/science.40.1041.857.
2. K.Takeuchi, M.Soda, Y.Togashi, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381.
3. E.Check Hayden. Is the $1,000 genome for real? Nature. 2014. doi:10.1038/nature.2014.14530.
4. T.J.Hudson, W.Anderson, A.Artez, et al. International network of cancer genome projects. Nature. 2010;464(7291):993–998.
5. J.N.Weinstein, E.A.Collisson, G.B.Mills, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120.
6. R.Soong, N.Syn, K.Wang, et al. Precision oncology: mind the disruption. Biochem |Biochem Soc. 2016;38(1):14–18.
7. M.Schena, D.Shalon, R.W.Davis, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467–470.
8. T.R.Golub, D.K.Slonim, P.Tamayo, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531–537.
9. A.A.Alizadeh, M.B.Eisen, R.E.Davis, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
10. L.J.van ’t Veer, H.Dai, M.J.van de Vijver, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536.
11. S.Paik, S.Shak, G.Tang, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–2826.
12. M.Margulies, M.Egholm, W.E.Altman, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376–380.
13. T.J.Lynch, D.W.Bell, R.Sordella, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
14. A.Lièvre, J.-B.Bachet, D.Le Corre, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.
15. G.H.Lyman, H.L.Moses, Biomarker tests for molecularly targeted therapies: laying the foundation and fulfilling the dream. J Clin Oncol. 2016;34:2061–2066. JCO.2016.67.3160–
16. P.L.Bedard, A.R.Hansen, M.J.Ratain, et al. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–364.
17. L.A.Garraway. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806–1814.
18. D.J.Slamon, B.Leyland-Jones, S.Shak, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
19. Lessons learned from the development of a diagnostic to predict response to Herceptin. Available from: http://www.oecd.org/sti/biotech/35641278.pdf.
20. N.Thatcher, A.Chang, P.Parikh, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (London, England). 2005;366(9496):1527–1537.
21. A.T.Shaw, D.-W.Kim, R.Mehra, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197.
22. A.T.Shaw, D.-W.Kim, K.Nakagawa, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
23. R.Dienstmann, J.Rodon, J.Tabernero. Optimal design of trials to demonstrate the utility of genomically-guided therapy: putting precision cancer medicine to the test. Mol Oncol. 2015;9(5):940–950.
24. D.D.Von Hoff, J.J.Stephenson, P.Rosen, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–4883.
25. E.S.Kim, R.S.Herbst, I.I.Wistuba, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.
26. A.Lopez-Chavez, A.Thomas, A.Rajan, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000–1007.
27. ASCO 2013: first prospective trial shows molecular profiling timely for tailoring therapy. Available from: http://www.ascopost.com/News/5231.
28. M.G.Kris, B.E.Johnson, L.D.Berry, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
29. NCI and the Precision Medicine Initiative. Available from: http://www.cancer.gov/research/key-initiatives/precision-medicine.
30. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial. Available from: http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match.
31. N.L.-X.Syn, W.-P.Yong, S.-C.Lee, et al. Genetic factors affecting drug disposition in Asian cancer patients. Expert Opin Drug Metab Toxicol. 2015;11(12):1879–1892.
32. S.Matsumoto, K.Yoh, T.Seto, et al. Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan). ASCO Meet Abstr. 2015;33(15_suppl):8093.
33. D.V.T.Catenacci, B.N.Polite, L.Henderson, et al. Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity–PANGEA. ASCO Meet Abstr. 2014;32(3_suppl):66.
34. L.A.Chantrill, A.M.Nagrial, C.Watson, et al. Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clin Cancer Res. 2015;21(9):2029–2037.
35. F.André, T.Bachelot, F.Commo, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267–274.
36. C.Le Tourneau, J.-P.Delord, A.Gonçalves, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334.
37. M.C.Garassino, O.Martelli, M.Broggini, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–988.
38. Q.Zhou, Y.Cheng, -J.-J.Yang, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol. 2014;25(12):2385–2391.
39. T.Kawaguchi, M.Ando, K.Asami, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014;32(18):1902–1908.
40. V.Gregorc, S.Novello, C.Lazzari, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014;15(7):713–721.
41. T.S.Mok, Y.-L.Wu, S.Thongprasert, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
42. F.Andre, E.Mardis, M.Salm, et al. Prioritizing targets for precision cancer medicine. Ann Oncol. 2014;25(12):2295–2303.
43. C.A.Drukker, H.van Tinteren, M.K.Schmidt, et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat. 2014;143(3):587–592.
44. J.A.Sparano, R.J.Gray, D.F.Makower, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–2014.
45. B.Győrffy, C.Hatzis, T.Sanft, et al. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11.
46. K.Fizazi, F.A.Greco, N.Pavlidis, et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl_6):vi64–8.
47. N.Pavlidis, G.Pentheroudakis. Cancer of unknown primary site. Lancet (London, England). 2012;379(9824):1428–1435.
48. G.R.Varadhachary, M.N.Raber. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757–765.
49. F.A.Greco, D.R.Spigel, D.A.Yardley, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15(5):500–506.
50. E.Meiri, W.C.Mueller, S.Rosenwald, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012;17(6):801–812.
51. G.Pentheroudakis, N.Pavlidis, G.Fountzilas, et al. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer. 2013;12:57.
52. K.A.Hoadley, C.Yau, D.M.Wolf, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–944.
53. B.Khademi, J.Mahmoudi, A.Monabati, et al. Molecular diagnosis of nasopharyngeal carcinoma using detection of Epstein-Barr virus latent membrane protein-1 gene in cervical metastatic lymph nodes. Am J Otolaryngol. 2009;30(2):95–100.
54. G.Fotopoulos, N.Pavlidis. The role of human papilloma virus and p16 in occult primary of the head and neck: a comprehensive review of the literature. Oral Oncol. 2015;51(2):119–123.
55. E.L.Kwak, D.R.Camidge, J.Clark, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. ASCO Meet Abstr. 2009;27(15S):3509.
56. E.L.Kwak, Y.-J.Bang, D.R.Camidge, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
57. K.V.M.Huber, E.Salah, B.Radic, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508(7495):222–227.
58. K.Bergethon, A.T.Shaw, S.-H.I.Ou, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870.
59. U.McDermott, A.J.Iafrate, N.S.Gray, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68(9):3389–3395.
60. A.T.Shaw, S.-H.I.Ou, Y.-J.Bang, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
61. K.Flaherty, I.Puzanov, J.Sosman, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. ASCO Meet Abstr. 2009;27(15S):9000.
62. K.T.Flaherty, I.Puzanov, K.B.Kim, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
63. P.B.Chapman, A.Hauschild, C.Robert, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
64. S.Nik-Zainal, P.Van Loo, D.C.Wedge, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994–1007.
65. V.Almendro, Y.-K.Cheng, A.Randles, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014;6(3):514–527.
66. L.A.Diaz, R.T.Williams, J.Wu, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540.
67. S.Misale, R.Yaeger, S.Hobor, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
68. S.-H.Tan, N.S.Sapari, H.Miao, et al. High-throughput mutation profiling changes before and 3 weeks after chemotherapy in newly diagnosed breast cancer patients. PLoS One. 2015;10(12):e0142466.
69. M.Garg, Y.Nagata, D.Kanojia, et al. Profiling of somatic mutations of acute myeloid leukemia, FLT3-ITD subgroup at diagnosis and relapse. Blood. 2015;126(22):2491–2501.
70. S.-C.Lee, X.Xu, W.-J.Chng, et al. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenet Genomics. 2009;19(11):833–842.
71. D.V.T.Catenacci. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967–996.
72. A.M.Newman, C.L.Liu, M.R.Green, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
73. A.J.Gentles, A.M.Newman, C.L.Liu, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.• This paper applies a previously-published algorithm (CIBERSORT) for inferring immune cell abundance from bulk tumour transcriptomes, but go on further to demonstrate novel associations between immune cell proportions and survival outcomes.
74. A.J.Gentles, B.S VB, L.J.Lee, et al. Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non-small cell lung cancer. J Natl Cancer Inst. 2015;107(10):djv211.
75. S.A.Shukla, M.S.Rooney, M.Rajasagi, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152–1158.• Traditionally, determination of HLA genotypes was a complex process which required specialised kits. In this paper, the authors develop a bioinformatics pipeline to infer HLA mutations from whole-exome sequencing data, and use it to analyse a large series of tumour samples.
76. T.I.Zack, S.E.Schumacher, S.L.Carter, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–1140.
77. A.J.Bass, V.Thorsson, I.Shmulevich, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209.
78. L.B.Alexandrov, S.Nik-Zainal, D.C.Wedge, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
79. B.E.Bernstein, E.Birney, I.Dunham, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.
80. I.R.Watson, K.Takahashi, P.A.Futreal, et al. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703–718.
81. E.Khurana, Y.Fu, D.Chakravarty, et al. Role of non-coding sequence variants in cancer. Nat Rev Genet. 2016;17(2):93–108.
82. F.W.RreHuang, E.Hodis, M.J.Xu, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957–959.
83. S.Horn, A.Figl, P.S.Rachakonda, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959–961.
84. D.A.Oldridge, A.C.Wood, N.Weichert-Leahey, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015;528:418–421. doi:10.1038/nature15540.
85. X.S.Puente, S.Beà, R.Valdés-Mas, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519–524.•• Using whole-genome sequencing, this paper defined novel potential drivers of cancer in the non-coding region of the genome. This is a highly significant development as the non-coding portion of the cancer genome has been largely unexplored in the past due to technological limitations.
86. K.Wang, S.T.Yuen, J.Xu, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–582.
87. A.-M.Patch, E.L.Christie, D.Etemadmoghadam, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–494.
88. N.Waddell, M.Pajic, A.-M.Patch, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.
89. M.Gerlinger, A.J.Rowan, S.Horswell, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892.
90. Y.Xiao, G.J.Freeman. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5(1):16–18.
91. D.T.Le, J.N.Uram, H.Wang, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
92. N.A.Rizvi, M.D.Hellmann, A.Snyder, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
93. N.Syn, L.Wang, G.Sethi, et al. Exosome-mediated metastasis: from epithelial–Mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci. 2016. doi:10.1016/j.tips.2016.04.006.• This review article advances the concept that exosome vesicles released by tumours contain a functional molecular cargo which is crucial in facilitating all steps of the invasion-metastasis cascade, thus supporting the profiling of tumour-derived exosomes for prognostic and predictive biomarkers.
94. S.A.Melo, L.B.Luecke, C.Kahlert, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182.
95. M.G.Best, N.Sol, I.Kooi, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–676.
96. S.-J.Dawson, D.W.Y.Tsui, M.Murtaza, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
97. A.L.A.Wong, J.S.J.Lim, A.Sinha, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015;13:1–9.
98. G.N.Hortobagyi, D.Chen, M.Piccart, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2015;34(5):419–426.
99. A.Prahallad, C.Sun, S.Huang, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103.
100. S.Turajlic, S.J.Furney, G.Stamp, et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol. 2014;25(5):959–967.
101. G.Iyer, A.J.Hanrahan, M.I.Milowsky, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.
102. M.Arnedos, C.Vicier, S.Loi, et al. Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol. 2015;12(12):693–704.
103. G.M.Frampton, A.Fichtenholtz, G.A.Otto, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
104. N.S.Sapari, E.Elahi, M.Wu, et al. Feasibility of low-throughput next generation sequencing for germline DNA screening. Clin Chem. 2014;60(12):1549–1557.